EGFR and breast carcinoma: To examine the significance of downregulation of receptor expression on breast cancer cell proliferation, MCF7, T47D, BT474, and MDA-MB231 cells were cultured with EGFR tyrosine kinase inhibitor erlotinib (Figure 4D) or ER antagonist tamoxifen (Figure 4E).